Shanghai Chest Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1957-01-01
- Employees
- -
- Market Cap
- -
A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
Phase 2
Not yet recruiting
- Conditions
- EGFR Mutation Positive Advanced Non Small Cell Lung CancerPD-L1 Positive
- Interventions
- Drug: Limertinib+bevacizumab
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 136
- Registration Number
- NCT06982924
MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer
Not Applicable
Not yet recruiting
- Conditions
- Lung Cancer (NSCLC)
- Interventions
- Device: MWADrug: TKI
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06969781
Transbronchial MWA for Pulmonary Tumors
Not Applicable
Not yet recruiting
- Conditions
- Lung Cancer
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06969014
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Phase 2
Not yet recruiting
- Conditions
- Esophageal Cancer Stage III
- Interventions
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06965829
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung CancerNon-Small-Cell Lung Cancer Stage IV
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT06962449
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
RAB Versus Ultrathin Bronchoscopy With VBN in the Diagnosis of PPNs
Not Applicable
Not yet recruiting
- Conditions
- Peripheral Pulmonary Nodules
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 184
- Registration Number
- NCT06962436
- Locations
- 🇨🇳
Shandong Public Health Clinical Center, Jinan, Shandong, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
Phase 2
Not yet recruiting
- Conditions
- KRAS G12C Lung Cancer
- Interventions
- Drug: IBI351+AK112
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06936644
EBUS-TTFB vs EBUS-TBNA for Diagnosing Inadequate Lymph Node Specimens Based on MOSE
Not Applicable
Recruiting
- Conditions
- Lymphadenopathy
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 162
- Registration Number
- NCT06913569
- Locations
- 🇨🇳
The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Huzhou Central Hospital, Huizhou, Zhejiang, China
GGO-dominant PPLs Diagnosis Using CLE and ssRAB-guided Cryobiopsy
Not Applicable
Not yet recruiting
- Conditions
- Lung Ground-Glass Opacity
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 119
- Registration Number
- NCT06910046
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC
Not yet recruiting
- Conditions
- ALK-Positive NSCLC
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06904547
© Copyright 2025. All Rights Reserved by MedPath